Patents by Inventor Vittoria ZINZALLA

Vittoria ZINZALLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 11952418
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: April 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • LRP5 and PD-1 antagonist anticancer combination therapy
    Patent number: 11578129
    Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Markus Johann Bauer, Barbara Drobits-Handl
  • POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20220362393
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 17, 2022
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 11033636
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 15, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • ANTICANCER COMBINATION THERAPY
    Publication number: 20200308276
    Abstract: The invention describes anti-cancer therapies comprising using an polypeptide capable of specifically binding to LRP5 and LRP6 in combination with an anti-PD1 antibody, each as described herein.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Vittoria ZINZALLA, Markus Johann BAUER, Barbara DROBITS-HANDL
  • ANTICANCER COMBINATION THERAPY
    Publication number: 20200308283
    Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Vittoria ZINZALLA, Markus Johann BAUER, Barbara DROBITS-HANDL
  • BIPARATOPIC POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20200199222
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 25, 2020
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 10597449
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 24, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20180344868
    Abstract: The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
  • BIPARATOPIC POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
    Publication number: 20170174762
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 22, 2017
    Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE